Co-Diagnostics, Inc. Aktie News

SALT LAKE CITY , April 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close. The Company will also host a conference call and webcast on the same day ...

SALT LAKE CITY , April 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference (APRC) of the International Union Agains...

Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY , April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing ...

SALT LAKE CITY , April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to...

Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY, March 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address at the 5th Annual Ma...

SALT LAKE CITY, Utah , March 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, ...

Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript

SALT LAKE CITY , March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year  2023 Financial Results: Revenue of $6.8 million, down from $34.2 million during the prior year primarily due...